Thomas S. Lin

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 690 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn et al. · Blood · 2004 · 403 citations · Full text

Medicine, Oncology, Pharmacology +16

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

John C. Byrd, Thomas S. Lin, James T. Dalton et al. · Blood · 2006 · 388 citations · Full text

Medicine, Oncology, Pharmacology +7

Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia

Aparna Raval, Stephan M. Tanner, John C. Byrd et al. · Cell · 2007 · 368 citations · Full text

Life Sciences, Cancer Biology, Oncology +14

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Neil E. Kay, Susan M. Geyer, Timothy G. Call et al. · Blood · 2006 · 293 citations · Full text

Pharmacy, Immunology, Oncology +14